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Abstract
Background: Detoxification in the liver involves activation of nuclear receptors, such as the
constitutive androstane receptor (CAR), which regulate downstream genes of xenobiotic
metabolism. Frequently, the metabolism of endobiotics is also modulated, resulting in potentially
harmful effects. We therefore used 1,4-Bis [2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) to
study the effect of CAR activation on mouse hepatic transcriptome and lipid metabolome under
conditions of diet-induced hyperlipidemia.
Results: Using gene expression profiling with a dedicated microarray, we show that xenobiotic
metabolism, PPARα and adipocytokine signaling, and steroid synthesis are the pathways most
affected by TCPOBOP in normal and hyperlipidemic mice. TCPOBOP-induced CAR activation
prevented the increased hepatic and serum cholesterol caused by feeding mice a diet containing 1%
cholesterol. We show that this is due to increased bile acid metabolism and up-regulated removal
of LDL, even though TCPOBOP increased cholesterol synthesis under conditions of
hyperlipidemia. Up-regulation of cholesterol synthesis was not accompanied by an increase in
mature SREBP2 protein. As determined by studies in CAR -/- mice, up-regulation of cholesterol
synthesis is however CAR-dependent; and no obvious CAR binding sites were detected in
promoters of cholesterogenic genes. TCPOBOP also affected serum glucose and triglyceride levels
and other metabolic processes in the liver, irrespective of the diet.
Conclusion: Our data show that CAR activation modulates hepatic metabolism by lowering
cholesterol and glucose levels, through effects on PPARα and adiponectin signaling pathways, and
by compromising liver adaptations to hyperlipidemia.
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Background
The liver is the central organ of metabolic and energy
homeostasis. It regulates levels of endogenous metabo-
lites such as glucose, triglycerides and cholesterol, and
detoxifies xenobiotics. These endobiotic and xenobiotic
metabolic processes are frequently regulated by the same
nuclear receptors. CAR, the constitutive androstane recep-
tor, was initially described as a pure xenosensor of the
liver. It activates the detoxification system in the presence
of drugs and endogenous molecules, such as bile acids
and bilirubin. Therefore, CAR activators are used to treat
cholestasis and jaundice in humans and mice [1-4].
TCPOBOP (1,4-Bis [2-(3,5-dichloropyridyloxy)]benzene)
and phenobarbital, two representative CAR activators,
have strong tumor-promoting effects in mice. They
increase hepatocyte proliferation, suppress apoptosis
[5,6] and through c-Myc and FoxM1 mediated pathways
stimulate the proliferative program leading to liver hyper-
plasia [7]. CAR activators also increase metabolism of the
thyroid hormone and thereby affect metabolic homeosta-
sis [4].
The fact that CAR is not only a xenosensor but also has a
role in the endogenous liver metabolism has recently
been accepted. For example, long-term treatment with
phenobarbital lowered plasma glucose levels in non-insu-
lin-dependent diabetic patients [8]. This has been
explained by CAR-dependent repression of mouse liver
gluconeogenesis through a mechanism involving HNF4α
and FoxO1 [9-12]. Phenobarbital also increases serum
triglycerides in patients and mice [13-16]. This was recog-
nized as a CAR-dependent effect where the CAR pathway
interacts with PPARα signaling, which is crucial for main-
tenance of liver lipid homeostasis [16]. A PPARα-CAR
inverse regulation has been implicated in inhibiting the β-
oxidation of fatty acids, and CAR inverse agonists were
proposed as potential drugs for non-alcoholic fatty liver
disease (NAFLD) [16,17]. Another side-effect of pheno-
barbital is an increase in total serum cholesterol in
humans and rats [14,18], which results in increased the
hepatic cholesterol synthesis by an as-yet undetermined
mechanism [12,18]. Most recently, CAR activation in
mice was shown to decrease circulating HDL, probably by
down-regulating ApoA-I gene expression [19].
Despite numerous studies regarding the beneficial or
harmful roles of activated CAR, little is known regarding
the role of CAR and its cross–talks with metabolic proc-
esses in the liver of cholesterol fed mice. This study
describes the systemic effect of CAR activation by
TCPOBOP on the mouse hepatic transcriptome and lipid
metabolome in a state of diet-induced hyperlipidemia.
Results
Cholesterol homeostasis
Effect of TCPOBOP
Treatment of normal chow fed mice with TCPOBOP
resulted in lower total serum cholesterol, as a result of
reduced LDL- and HDL-cholesterol (Table 1). The liver
transcriptome data as measured by microarrays (Table 2)
provide an explanation. Up-regulation of the LDL recep-
tor gene (Ldlr) and the cholesterol ester-break down
enzyme (Lip1) reflect higher up-take of LDL particles from
blood to the liver. At the same time Acat2, which is prima-
rily responsible for formation of cholesterol esters des-
tined for VLDL, is down-regulated. Several genes linked to
the uptake of HDL to the liver (Scarb1), cholesterol efflux
to lipid poor apolipoproteins (Abca1), or representing
parts of either HDL particles or chylomicrons remnants
(Apoa5,  Apoe, and Saa) were down-regulated. Due to
higher liver uptake of LDL cholesterol from serum and
lower HDL cholesterol efflux, we would expect an increase
in total liver cholesterol. In fact, total liver cholesterol has
been lowered (Figure 1A, pale grey boxes). Transcriptome
data indicated that this may be due to increased bile acid
synthesis, but of the alternative pathways (Cyp27a1,
Cyp39a1, and Cyp7b1). The ratio of C4, an intermediate of
the classical CYP7A1 pathway, to liver cholesterol (Figure
1C, pale grey boxes), shows an increase in bile acid syn-
thesis, although RNA measurements did not confirm
Cyp7a1 up-regulation (RT-PCR – Table 3). RT-PCR analy-
sis reveals considerable inter-individual differences in the
Table 1: Serum parameters in TCPOBOP treated mice.
Treatment Vehicle TCPOBOP Vehicle TCPOBOP
Diet Standard Standard 1% cholesterol 1% cholesterol
Total cholesterol (mmol/L) 3.21 ± 1.52 1.91 ± 0.21* 4.09 ± 0.80* 2.67 ± 0.61#
LDL-cholesterol (mmol/L) 0.33 ± 0.05 0.12 ± 0.02* 0.68 ± 0.06* 0.34 ± 0.09#
HDL-cholesterol (mmol/L) 1.03 ± 0.05 0.81 ± 0.18* 1.76 ± 0.39* 1.46 ± 0.37
Total triglyceride (mmol/L) 0.54 ± 0.1 0.82 ± 0.12* 1.39 ± 0.43* 1.15 ± 0.25
Glucose (mmol/L) 9.67 ± 0.68 8.59 ± 1.73 12.1 ± 2.16* 10.45 ± 1.83#
Serum parameters in mice fed either standard or 1% cholesterol diet and treated either vehicle or TCPOBOP. Each value represents mean ± SD of 
6 mice per group. Student t-test was used for calculation of statistical significance (p < 0.05). *Statistical significance compared to vehicle treated 
group on standard diet. #Statistical significance compared to vehicle treated group on high-cholesterol diet.BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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Table 2: Differentially expressed genes involved in cholesterol homeostasis in mouse liver after TCPOBOP treatment
TCPOBOP + normal chow diet Vehicle + cholesterol diet TCPOBOP + cholesterol diet
Gene Symbol Gene Description Log2 ratio p-value Log2 ratio p-value Log2 ratio p-value
Cholesterol biosynthesis
Sc4mol Sterol-C4-methyl 
oxidase-like
nc nc -2.50 0.000 1.85 0.001
Cyp51 Cytochrome P450, 
51a1
nc nc -1.86 0.001 1.27 0.008
Hmgcs1 3-hydroxy-3-
methylglutaryl-
Coenzyme A synthase 
1
nc nc -1.79 0.001 1.20 0.015
Fdps Farnesyl diphosphate 
synthase 1
nc nc -1.73 0.001 0.99 0.026
Fdft1 Farnesyl diphosphate 
farnesyl transferase 1, 
Squalene synthase
nc nc -1.69 0.000 1.08 0.006
Nsdhl NAD(P) dependent 
steroid 
dehydrogenase-like
nc nc -1.35 0.004 0.99 0.033
Lss Lanosterol synthase 0.60 0.033 -1.31 0.000 0.81 0.012
Mvd Mevalonate 
(diphospho) 
decarboxylase
nc nc -1.27 0.002 0.88 0.017
Mvk Mevalonate kinase nc nc -1.18 0.001 0.86 0.010
Hmgcr 3-hydroxy-3-
methylglutaryl-
Coenzyme A 
reductase
0.99 0.001 -1.14 0.001 1.09 0.008
Sqle Squalene epoxidase 0.49 0.014 -1.11 0.014 nc nc
Dhcr24 24-dehydrocholesterol 
reductase
nc nc -0.57 0.019 0.54 0.018
Dhcr7 7-dehydrocholesterol 
reductase
nc nc -0.36 0.049 nc nc
Idi1 Isopentenyl-
diphosphate delta 
isomerase
nc nc 0.39 0.003 nc nc
Sc5d Sterol-C5-desaturase 
homolog
0.36 0.029 nc nc nc nc
SREBP signaling pathway
Insig1 Insulin induced gene 1 0.82 0.000 nc nc nc nc
Mbtps1 Membrane-bound 
transcription factor 
peptidase, site 1
1.72 0.000 nc nc 2.06 0.003
Insig2 Insulin induced gene 2 1.94 0.000 0.25 0.038 1.24 0.000
Bile acid synthesis
Cyp8b1 Cytochrome P450, 
8b1
-2.16 0.000 nc nc -0.67 0.036
Cyp7b1 Cytochrome P450, 
7b1
0.21 0.014 nc nc nc nc
Cyp27a1 Cytochrome P450, 
27a1
0.73 0.000 nc nc 0.46 0.028
Cyp39a1 Cytochrome P450, 
39a1
1.06 0.000 nc nc 0.91 0.000
Lipid transport
Apoa5 Apolipoprotein A-V -0.57 0.013 nc nc -0.45 0.039
Apoe Apolipoprotein E -0.38 0.019 nc nc -0.46 0.022
Ldlr Low density 
lipoprotein receptor
0.32 0.017 -0.38 0.037 0.42 0.039
Apoa4 Apolipoprotein A-IV 2.23 0.000 1.09 0.000 1.00 0.001
Transporters
Abca1 ATP-binding cassette, 
sub-family A (ABC1), 
member 1
-0.39 0.024 0.18 0.040 -0.38 0.015BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
Page 4 of 15
(page number not for citation purposes)
level of Cyp7a1 expression, resulting in a lack of statistical
significance. Down-regulation of Cyp8b1 and up-regula-
tion of alternative bile acid synthesis could lead to pro-
duction of more hydrophilic muricholates and therefore
to a potential change in composition of the bile [20].
Microarray data also indicate the influence of CAR activa-
tion on enterohepatic circulation. As described before,
CAR stimulated hepatic export system of bile acids
through canalicular (Abcc2,  Abcb11) and basolateral
(Abcc3) bile acid transporters, but also uptake in the liver
(Slco1a4) (Table 2). Four genes involved in cholesterol
biosynthesis (Hmgcr, Sqle, Lss, and Sc5d) were up-regu-
Abcb11 ATP-binding cassette, 
sub-family B (MDR/
TAP), member 11
0.46 0.001 0.68 0.000 nc nc
Abcc2 ATP-binding cassette, 
sub-family C (CFTR/
MRP), member 2
0.92 0.000 nc nc 0.89 0.000
Slco1a4 Solute carrier organic 
anion transporter 
family, member 1a4
1.04 0.000 -0.98 0.000 1.66 0.000
Abcc3 ATP-binding cassette, 
sub-family C (CFTR/
MRP), member 3
1.29 0.000 -0.76 0.003 2.06 0.000
Abcg8 ATP-binding cassette, 
sub-family G (WHITE), 
member 8
nc nc nc nc -1.02 0.006
Abcg5 ATP-binding cassette, 
sub-family G (WHITE), 
member 5
nc nc nc nc -0.87 0.008
Slco2b1 Solute carrier organic 
anion transporter 
family, member 2b1
-0.40 0.001 0.25 0.009 nc nc
Other
Scarb1 Scavenger receptor 
class B, member 1
-0.87 0.000 0.31 0.003 -0.88 0.000
Acat2 Acetyl-Coenzyme A 
acetyltransferase 2
-0.31 0.010 nc nc -0.33 0.019
Lip1 Lysosomal acid lipase 1 0.49 0.000 0.38 0.002 0.28 0.043
Saa2 Serum amyloid A 2 -3.60 0.000 nc nc -3.28 0.001
Saa1 Serum amyloid A 1 -3.52 0.000 nc nc -3.22 0.001
Saa3 Serum amyloid A 3 -3.39 0.000 nc nc -2.87 0.001
Differentially expressed genes involved in cholesterol homeostasis in mouse liver after TCPOBOP treatment or cholesterol diet as detected by the 
Steroltalk microarray. Data represent log2 ratios of TCPOBOP treated versus vehicle treated on the same diet (standard or cholesterol) and 
vehicle treated group on cholesterol diet versus standard diet. Six animals per group were used and p-value was calculated using t-test as 
implemented in BRB-Array Tools. GeneBank accession numbers are available in Additional file 1. nc – no change.
Table 2: Differentially expressed genes involved in cholesterol homeostasis in mouse liver after TCPOBOP treatment (Continued)
Table 3: Expression of genes in wild type mice treated with TCPOBOP as detected by RT-PCR
Treatment TCPOBOP Untreated TCPOBOP
Diet Standard diet 1%cholesterol vs standard diet 1%cholesterol diet
Hmgcr 3.09 ± 2.93* 0.27 ± 0.14* 2.42 ± 0.76*
Cyp51a1 1.80 ± 1.49 0.34 ± 0.24* 3.00 ± 1.33*
Srebp2 1.18 ± 0.56 0.41 ± 0.11* 1.58 ± 0.47*
Insig1 2.66 ± 2.19* 0.96 ± 0.42 1.36 ± 0.53
Insig2a 8.34 ± 5.54* 1.43 ± 0.32* 2.78 ± 1.12*
Insig2b 0.24 ± 0.11* 0.74 ± 0.20 0.37 ± 0.20*
Cyp7a1 1.29 ± 1.74 0.85 ± 0.44 0.81 ± 0.64
Cyp8b1 0.34 ± 0.41* 0.69 ± 0.29 0.43 ± 0.22*
Cyp2b10 291.4 ± 194.5* 1.04 ± 0.31 135.4 ± 40.5*
Cyp3a11 11.17 ± 6.13* / 10.8 ± 4.98*
The expression of key genes involved in cholesterol homeostasis and drug metabolism as measured by RT-PCR. Data represents fold change ± 
standard deviation of TCPOBOP treated versus vehicle treated on standard diet, cholesterol diet, and vehicle treated group on cholesterol diet 
versus standard diet. Six animals per group were analyzed and statistical significance was determined using Student t-test. Unigene symbols are used 
as abbreviations. *p < 0.05.BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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Liver sterol profiles in TCPOBOP treated mice Figure 1
Liver sterol profiles in TCPOBOP treated mice. Liver sterol profiles in mice as measured by GC-MS (3 biological sam-
ples per group) fed either standard (light box) or 1% cholesterol diet (dark box), and treated either vehicle or TCPOBOP. p-
values are indicated between different groups. A. Total liver cholesterol level (ng/mg liver). B. Free lathosterol/total cholesterol 
level ratio indicates the metabolic rate of liver cholesterol biosynthesis. C. Free C4 (7-α-hydroxy-4-cholestene-3-one)/total 
cholesterol ratio. C4 is an intermediate in bile acid biosynthesis and shows a metabolic rate of the classical CYP7A1 pathway.
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lated (Table 2 and 3); however, the ratio of lathosterol to
cholesterol did not confirm increased cholesterol biosyn-
thesis (Figure 1B, pale grey boxes). Many genes of the
SREBP2 signaling pathway, the main regulatory pathway
of cholesterol biosynthesis, are up-regulated (Mbtps1,
Insig1,  Insig2), but not Srebp2  itself (Table 3).
Diet-induced hyperlipidemia
One week of 1% cholesterol diet, as expected, increased
total cholesterol, HDL-, LDL-cholesterol, total triglycer-
ides and glucose levels (Table 1). The diet also increased
total liver cholesterol, resulting in repression of choles-
terol biosynthesis observed on the metabolite (Figure 1A
and 1B, dark grey boxes), and transcriptome levels
(microarrays – Table 2; RT-PCR – Table 3). Also Srebp2
and LDL receptor were down-regulated as a result of high
liver cholesterol. No changes were detected in primary,
CYP7A1-mediated bile acid synthesis pathway on metab-
olite (Figure 1C, dark grey boxes) or transcriptome levels.
However, bile acid transporters on basolateral and canal-
icular membranes were up-regulated (Abcb11, Slco2b1).
TCPOBOP in diet-induced hyperlipidemia
TCPOBOP treatment of hyperlipidemic animals has sig-
nificantly lowered serum total cholesterol levels, by low-
ering the LDL (Table 1). Liver transcriptome data show
up-regulation of LDL-receptor and enzyme for cholesterol
ester break-down (Lip1), and lower ester formation by
Acat2  (Table 2). However, levels of HDL-cholesterol
remain unchanged (Table 1), even if transcriptome data
revealed down-regulation of genes connected to HDL par-
ticles (Scarb1, Abca1, Apoa5, Apoe, and Saa), except for
Apoa4. TCPOBOP lowered the total liver cholesterol of
cholesterol-fed mice back to pre-diet levels (Figure 1A,
dark grey boxes). This result indicates that TCPOBOP can
induce removal of excess dietary cholesterol from the liver
and serum in mice. We again see increased primary
CYP7A1 pathway of bile acid synthesis on the metabolite
level, as indicated by C4 and cholesterol ratio (Figure 1C,
dark grey boxes), and no change in expression of Cyp7a1
(Table 3). We also see an increase in alternative bile acid
synthesis pathways (Cyp27a1, Cyp39a1), and down-regu-
lation of Cyp8b1, all leading to possible formation of
more hydrophilic muricholic bile acids. Down-regulation
of cholesterol transporter from liver to bile (Abcg5/Abcg8)
is also observed, again potentially affecting the composi-
tion of the bile (Table 2). Controversially, under these
high-cholesterol conditions, TCPOBOP has up-regulated
the liver cholesterol synthesis as measured by lathosterol
and cholesterol ratio (Figure 1B, dark grey boxes) and
transcriptome levels (microarrays – Table 2; RT-PCR –
Table 3).
In summary (Figure 2), CAR activation by TCPOBOP leads
to lower total serum cholesterol due to activation of the
LDL uptake from the circulation and repression of HDL
export. The paradoxical drop in liver cholesterol can be
explained by activation of the bile acid synthesis and acti-
vated pathways for bile efflux from the liver, enabling
removal of excess liver cholesterol. Even if the cholesterol
diet leads to increased serum and liver cholesterol and the
expected decrease in cholesterol synthesis capacity,
TCPOBOP is able to reverse these processes. A list of all
differentially expressed genes is available in Additional
file 1 and Additional file 2 is a more detailed figure depict-
ing TCPOBOP effects on mouse liver under normal and
1% cholesterol-containing diet.
Triglyceride and glucose metabolism
The role of TCPOBOP
The xenobiotic increased total serum triglycerides, but
had no effect on glucose levels (Table 1). Transcriptome
data are in agreement with elevated triglycerides (Table 4).
They indicate up-regulation of fatty acid synthesis (Fasn)
and ketogenesis (Hmgcl), down-regulation of degradation
of fatty acids (Cpt1a), and up-regulation of the gene
responsible for the formation of acetyl-CoA (Pdhb), a sub-
strate for cholesterol and fatty acid synthesis. Synthesis of
hepatic glycogen is down-regulated (the most down-regu-
lated gene was Ppp1r3c, which is imperative for expression
of glycogenic enzymes). This also holds for gluconeogen-
esis (Pck1), while glucose transport (Slc2a1, increased;
and  Slc2a4, decreased) is modulated. Several genes
involved in the regulation of glucose and fatty acid home-
ostasis were down-regulated (Adipor2, Foxa2, Sirt1, Cebpa,
Igf1, Ppara, Pparg), but Chrebp (Mlxipl) was up-regulated.
Diet-induced hyperlipidemia
Serum metabolite measurements show that the choles-
terol diet increased triglycerides and glucose (Table 1),
again in agreement with the liver transcriptome data
(Table 4). Strong up-regulation of stearoyl-CoA desatu-
rase 1 (Scd1) and Ppara was measured, which indicates
activation of the PPARα signaling pathway. Up-regulated
was also the leukotriene B4 omega-hydroxylase
(Cyp4f14), indicating an increase in fatty acid metabo-
lism. Gluconeogenesis (G6Pase, Gapdh) was up-regulated
while ketogenesis (Hmgcl) and glycogenesis (Ppp1r3c)
were down-regulated.
TCPOBOP in diet-induced hyperlipidemia
In mice fed a 1% cholesterol-containing diet, TCPOBOP
had no effect on total serum triglycerides but lowered the
serum glucose (Table 1). Liver transcriptome analysis
(Table 4) indicated up-regulation of the gene involved in
formation of acetyl-CoA (Pdhb) and ketogenesis (Hmgcl),
no change in fatty acid synthesis (Fasn), and down-regula-
tion of fatty acid metabolism (Scd1, Cpt1a, Ppara,
Cyp4f14). Glycogen synthesis (Ppp1r3c) and gluconeogen-
esis (Pck1, G6pase) were down-regulated and the glucoseBMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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Effects of TCPOBOP and cholesterol diet on liver cholesterol homeostasis Figure 2
Effects of TCPOBOP and cholesterol diet on liver cholesterol homeostasis. Effects of TCPOBOP and cholesterol 
diet on liver cholesterol metabolism. A. Effects of TCPOBOP in conditions of normal diet. B. Effects of 1 week 1% cholesterol 
diet. C. Effects of TCPOBOP in conditions of high-cholesterol diet. Bold solid arrow – increase, solid arrow – no change, 
dashed arrow – decrease.
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Table 4: Differentially expressed genes involved in glucose and triglyceride metabolism in mouse liver after TCPOBOP treatment
TCPOBOP + normal chow diet Vehicle + cholesterol diet TCPOBOP + cholesterol diet
Gene Symbol Gene Description Log2 ratio p-value Log2 ratio p-value Log2 ratio p-value
Carbohydrate metabolism
Pck1 Phosphoenolpyruvate carboxykinase 1, 
cytosolic
-0.47 0.042 nc nc -0.39 0.039
Pdhb Pyruvate dehydrogenase (lipoamide) 
beta
0.61 0.000 0.33 0.005 0.43 0.014
G6Pase Glucose-6-phosphatase catalytic nc nc 1.00 0.005 -1.26 0.000
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase
nc nc 0.49 0.016 nc nc
Fatty acid metabolism
Cpt1a Carnitine palmitoyltransferase 1a, liver -0.81 0.000 nc nc -0.38 0.004
Hmgcl 3-hydroxy-3-methylglutaryl-Coenzyme 
A lyase
0.31 0.008 -0.53 0.001 0.64 0.003
Fasn Fatty acid synthase 0.58 0.007 nc nc nc nc
Scd1 Stearoyl-Coenzyme A desaturase 1 nc nc 1.40 0.004 -1.32 0.018
Cyp4f14 Cytochrome P450, 4f14 nc nc 0.98 0.000 -0.72 0.000
Transcription regulators
Cebpa CCAAT/enhancer binding protein 
(C/EBP), alpha
-1.17 0.000 nc nc -0.99 0.000
Sirt1 Sirtuin 1, silent mating type information 
regulation 2, homolog 1
-0.40 0.010 nc nc nc nc
Foxa2 Forkhead box A2 -0.22 0.049 nc nc nc nc
Mlxipl MLX interacting protein-like, old 
Wbscr14 or Chrebp
0.94 0.000 1.05 0.000 0.32 0.047
Crem CAMP responsive element modulator nc nc 0.35 0.002 -0.35 0.016
Ppara Peroxisome proliferator activated 
receptor alpha
-0.84 0.000 0.53 0.035 -0.93 0.000
Pparg Peroxisome proliferator activated 
receptor gamma
-0.83 0.005 nc nc nc nc
Transporters
Slc2a4 Solute carrier family 2 (facilitated 
glucose transporter), member 4
-0.43 0.000 nc nc nc nc
Slc2a1 Solute carrier family 2 (facilitated 
glucose transporter), member 1
0.37 0.001 nc nc 0.32 0.011
Cell signaling
Ppp1r3c Protein phosphatase 1, regulatory 
(inhibitor) subunit 3C
-3.47 0.000 -0.39 0.015 -2.64 0.000
Igf1 Insulin-like growth factor 1 -1.08 0.000 0.69 0.000 -1.37 0.000
Adipor2 Adiponectin receptor 2 -0.85 0.000 nc nc -0.80 0.001
Differentially expressed genes involved in glucose and triglyceride metabolism in mouse liver after TCPOBOP treatment or cholesterol diet as detected by the Steroltalk microarray. Data represent log2 ratios 
of TCPOBOP treated versus vehicle treated on the same diet (standard or cholesterol) and vehicle treated group on cholesterol diet versus standard diet. Six animals per group were used and p-value was 
calculated using t-test as implemented in BRB-Array Tools. GeneBank accession numbers and are available in Additional file 1. nc – no change.BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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transporter (Slc2a1) up-regulated. Again, genes involved
in regulation of liver glucose metabolism (Igf1, Crem,
Cebpa, and Adipor2) were down-regulated with exception
of Chrebp, which was up-regulated.
Figure 3 summarizes the observed changes. CAR activa-
tion by TCPOBOP results in an increase of serum triglyc-
erides due to increased hepatic fatty acid synthesis and
lower fatty acid degradation. Even if the decrease in serum
glucose was not statistically significant, reduced hepatic de
novo glycogen and glucose synthesis is observed. A choles-
terol diet leads to increased triglycerides and glucose, due
to increased liver fatty acid metabolism, repressed glyco-
gen synthesis and activated gluconeogenesis. TCPOBOP is
again able to reverse the effect of the cholesterol diet. On
the level of triglycerides there is no change in the serum
and the hepatic fatty acid synthesis pathways are activated
and fatty acid degradation repressed. Serum glucose has
dropped due to the repressed gluconeogenesis and acti-
vated glucose import.
Data mining approaches
Gene annotations using GeneCodis and KEGG pathways
were used to evaluate the expert knowledge based conclu-
sions described above. For the TCPOBOP treatment, an
effect of CAR activation on Adipocytokine, PPAR and Insulin
signaling pathways has been exposed (Table 5). Pathways
Metabolism of xenobiotics by cytochrome P450, ABC transport-
ers, Arachidonic acid, and Linoleic acid metabolism were also
significant due to TCPOBOP induction of drug metabo-
lism. Hyperlipidemia strongly exposed only Biosynthesis
of steroids. Minor effects were repression of certain
enzymes in pathway of Metabolism of xenobiotics by cyto-
chromes P450, and importantly, activation of PPAR signal-
ing pathway, which is an adaptation to the diet. TCPOBOP
in diet-induced hyperlipidemia exposed pathway Biosyn-
thesis of steroids as a result of up-regulation of cholesterol
biosynthesis genes. Again we see the effect on PPAR and
Adipocytokine signaling. Inhibition of PPAR signaling repre-
sents a response to liver the adaptation on dietary lipids.
Pathways of drug metabolism were also exposed.
Expression of cholesterogenic genes depends on CAR but 
not SREBP2
TCPOBOP has up-regulated SREBP2 target genes in mice
fed a 1% cholesterol-containing diet for 1 week. This was
unexpected since, under excess cholesterol, the choles-
terol feedback loop should prevent proteolytic cleavage
and activation of SREBP2. To check whether TCPOBOP
would influence proteolytic activation of SREBP2, immu-
noblot analysis was performed. Figure 4 shows that
TCPOBOP and subsequent CAR activation did not
increase the SREBP2 active form in the nucleus. We there-
fore propose that the observed TCPOBOP up-regulation
of cholesterogenic genes is SREBP2 independent.
To evaluate whether the up-regulation of SREBP2 respon-
sive genes by TCPOBOP might be a direct effect of CAR,
RT-PCR analyses in livers of wild type and CAR knock-out
mice fed with standard chow diet were performed (Table
6). Three cholesterogenic genes (Hmgcr,  Cyp51a1  and
Sqle) and two genes from the SREBP signaling pathway
(Insig1, Srebp2) were selected while Cyp3a11 and Cyp2b10
served as positive controls for the CAR regulated genes. In
wild-type mice TCPOBOP increased the expression of
Hmgcr, Insig1 and Sqle while expression of Cyp51a1 and
Srebp2 remained unchanged. TCPOBOP in CAR deficient
mice lowered expression of all measured genes. Compari-
son of CAR -/- mice to wild-type showed a higher basal
expression of SREBP2-dependent genes. These results give
two possible hypotheses: CAR without the ligand might
serve as a direct or indirect regulator of these genes. Since
expression analysis indicated the possibility of direct reg-
ulation of SREBP-2 dependent genes by CAR, analysis of
Hmgcr, Sqle and Insig1 promoters was performed to search
for potential CAR binding sites. Using specialized soft-
ware for nuclear receptor binding site search NUBIScan
[21] we found no CAR (DR4, DR3, ER6) binding sites in
Hmgcr, Sqle promoters. However, a DR4 site in Insig1 pro-
moter was found, which was already confirmed experi-
mentally [22].
Discussion
Hyperlipidemias provoke cardiovascular diseases that
represent a major cause of deaths in the developed world.
Studies in recent years show that metabolic disturbances
in the liver contribute to metabolic diseases (i.e. diabetes,
nonalcoholic fatty liver disease (NAFLD)) and cardiovas-
cular diseases. Nuclear receptors, such as PPARs, LXR and
FXR, are important regulators of the metabolic network
and are the targets of new therapeutic agents for treatment
of metabolic disorders [23]. Increasing amounts of data
also indicate that constitutive androstane receptor CAR
plays a role in the development of metabolic disorders
[24].
In the present study, we investigated CAR activation by
TCPOBOP in diet-induced hyperlipidemia in the liver by
using a dedicated microarray approach, liver and serum
sterol measurements. CAR activation by TCPOBOP
resulted in systemic dyslipidemia that includes lower
serum LDL and HDL cholesterol and increased triglycer-
ides (Additional file 2). Lower LDL-cholesterol and total
plasma cholesterol are considered beneficial effects of
CAR activators that result from increased liver uptake of
lipoproteins by up-regulated LDLR. In addition, liver
pathways for the bile acid synthesis and their removal are
up-regulated, contributing to decreased serum and liver
cholesterol. We observed up-regulation of CYP7A1 path-
way, but only on metabolite level and not on RNA level.
This discrepancy is probably due to large inter-individualBMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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Effects of TCPOBOP and cholesterol diet on liver glucose and triglyceride metabolism Figure 3
Effects of TCPOBOP and cholesterol diet on liver glucose and triglyceride metabolism. Proposed effects of 
TCPOBOP and cholesterol diet on liver glucose and triglyceride metabolism. A. Effects of TCPOBOP in conditions of normal 
diet. B. Effects of 1 week 1% cholesterol diet. C. Effects of TCPOBOP in conditions of high-cholesterol diet. Bold solid arrow – 
increase, solid arrow – no change, dashed arrow – decrease.
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variations in CYP7A1 expression which affects statistical
significance. It seems that TCPOBOP activates both
CYP7A1 and CYP27A1 pathways; however, without a
detailed analysis of bile acid content it is not possible to
conclude to what extent each pathway is affected. In diet-
induced hyperlipidemia, which represents a lipid meta-
bolic disturbance per se, CAR activation by TCPOBOP
lowers total cholesterol and LDL, but not HDL choles-
terol, whereas triglycerides remain elevated. The choles-
terol diet by itself did not change the expression of the bile
acid pathways, while application of TCPOBOP led to sim-
ilar changes as in the control liver (Additional file 2). As a
consequence, in normal and hyperlipidemic livers this
may result in altered composition of bile. A parameter of
dyslipidemia is also the TCPOBOP-mediated repression
of cholesterol influx from HDL to the liver in normal and
hyperlipidemic mice, where HDL-cholesterol levels
remain elevated. The influence of TCPOBOP on forma-
tion of HDL was shown by another study, where CAR-
dependent decrease in HDL was linked to repression of
ApoA-I synthesis [19]. In our study, several acute phase
proteins, such as serum amyloids (Saa) and apolipopro-
tein A-V, were down-regulated, while apolipoprotein A-IV
was up-regulated. Low-grade inflammation is associated
with an increased risk of coronary events. The marker of
this is CRP (C-reactive protein) the expression of which
was increased in TCPOBOP treated normal and hyperlip-
idemic mice. However, whether the changes induced by
TCPOBOP are pro-atherogenic remains unknown.
The metabolic syndrome increases the risk for develop-
ment of cardiovascular diseases, and vice versa. Nonalco-
holic steatohepatitis (NASH) is a nonalcoholic fatty liver
disease (NAFLD). It develops from liver steatosis in the
Table 5: Gene annotation of differentially expressed genes
KEGG pathway No of genes Genes
TCPOBOP in normal mouse liver
Adipocytokine signaling pathway 10 Pck1, Adipor1, Ppara, Mapk9, Cpt1a, Slc2a1, Nfkbia, Stat3, Adipor2, Slc2a4
Metabolism of xenobiotics by cytochrome P450 8 Cyp1a2, Cyp2b13, Cyp2b10, Cyp2c40, Cyp2e1, Cyp2b9, Cyp3a25, Cyp3a13
PPAR signaling pathway 7 Pck1, Cyp8b1, Ppara, Apoa5, Cpt1a, Cyp27a1, Pparg
ABC transporters – General 6 Abcc2, Abcb11, Abca1, Abcc1, Abcb4, Abcc3
Complement and coagulation cascade 6 Hc, C2, C4bp, Serping1, C9, Fgb
Insulin signaling pathway 5 Pck1, Fasn, Mapk9, Ppp1r3c, Slc2a4
Arachidonic acid metabolism 5 Cyp2b13, Cyp2b10, Cyp2c40, Cyp2e1, Cyp2b9
Linoleic acid metabolism 5 Cyp1a2, Cyp2c40, Cyp2e1, Cyp3a25, Cyp3a13
Biosynthesis of steroids 4 Lss, Sqle, Hmgcr, Sc5d
Cholesterol diet
Biosynthesis of steroids 13 Dhcr7, Lss, Mvk, Nsdhl, Idi1, Cyp51a1, Sqle, Hmgcr, Mvd, Fdps, Fdft1, Dhcr24, Sc4mol
Metabolism of xenobiotics by cytochrome P450 4 Cyp2f2, Cyp2c40, Cyp3a25, Cyp3a13
PPAR signaling pathway 4 Ppara, Scd1, Scp2, Apoc3
Terpenoid metabolism 4 Idi1, Sqle, Fdps, Fdft1
TCPOBOP in hyperlipidemic mouse liver
Biosynthesis of steroids 10 Lss, Mvk, Nsdhl, Cyp51a1, Hmgcr, Mvd, Fdps, Fdft1, Dhcr24, Sc4mol
PPAR signaling pathway 7 Pck1, Cyp8b1, Ppara, Apoa5, Scd1, Cpt1a, Cyp27a1
Metabolism of xenobiotics by cytochrome P450 7 Cyp1a2, Cyp2b13, Cyp2b10, Cyp2c40, Cyp2b9, Cyp3a25, Cyp3a13
Adipocytokine signaling pathway 6 Pck1, Ppara, Cpt1a, Slc2a1, Adipor2, Mapk8
Arachidonic acid metabolism 6 Cyp2b13, Cyp2b10, Cyp2c40, Cyp2b9, Cyp4f14
ABC transporters – General 5 Abcg5, Abcc2, Abca1, Abcc3, Abcg8
Linoleic acid metabolism 5 Pla2g6, Cyp1a2, Cyp2c40, Cyp3a25, Cyp3a13
Complement and coagulation cascade 5 C2, C4bp, Serping1, C9, Fgb
Butanoate metabolism 4 Hmgcl, Hmgcs1, Acat2, Pdhb
Gene annotation of differentially expressed genes using GeneCodis software and KEGG pathways, showing only pathways with at least four genes. 
Down-regulated genes are underlined.
Representative immunoblot analysis of nuclear SREBP2 in  mouse liver Figure 4
Representative immunoblot analysis of nuclear 
SREBP2 in mouse liver. Representative immunoblot anal-
ysis of nuclear SREBP2 in the liver of mice on standard or 
cholesterol diet and treated with TCPOBOP. No activation 
of SREBP2 was observed after TCPOBOP application. Diet: 
ST – standard diet, CH – cholesterol diet.
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presence of oxidative stress, insulin resistance, hepatotox-
ins and other factors [25]. A study of diet induced NASH
in mice showed that CAR activation by TCPOBOP
increased lipid peroxidation and oxidative stress, and
thereby contributes to the development of NASH [17].
Another aspect of CAR activation and development of
NAFLD is the effect of CAR on adiponectin, an adipocyte
hormone, and on the PPARα signaling pathway as indi-
cated by pathway analysis of our transcriptome data in
normal and hyperlipidemic liver. Adiponectin can pre-
vent the development of diabetes and metabolic syn-
drome, as it stimulates glucose utilization and fatty acid
combustion in the liver [26]. Our transcriptome analysis
indeed reveals that several genes of the adiponectin sign-
aling are modulated. For instance, the adiponectin recep-
tor II was down-regulated, a phenomenon also observed
in patients with NASH [27]. Adiponectin stimulation of
fatty acid degradation is mediated by PPARα and CAR
inhibition of this pathway might further contribute to
promotion of a metabolic syndrome. More importantly,
up-regulation of the PPARα signaling pathway is also an
adaptation of the liver to hyperlipidemia, and TCPOBOP
disturbed this adaptation. CAR also increased expression
of Chrebp, which stimulates fatty acid synthesis [28]. Our
data thus indicate that CAR activation in some aspects
mimics the effect of insulin on the liver. CAR, similarly to
insulin, inhibits liver fatty acid oxidation, gluconeogene-
sis and stimulates fatty acid synthesis and glycolysis. How-
ever, unlike insulin, CAR activation represses glycogen
synthesis. It therefore seems that CAR stimulates glucose
metabolism to acetyl-CoA, which can have a positive
effect on elevated plasma glucose levels, as seen in hyper-
lipidemic mice. However, acetyl-CoA is used later for fatty
acid and cholesterol synthesis. Elevated cholesterol bio-
synthesis does not result in higher liver or plasma levels,
because CAR also up-regulates cholesterol removal path-
ways. However, increased fatty acid synthesis and
repressed oxidation represent an important contribution
of CAR to the development of NAFLD.
Interestingly, TCPOBOP-induced CAR also up-regulated
cholesterol synthesis in hyperlipidemic liver and affected
the SREBP signaling pathway [29]. Our transcriptome
data indicate that TCPOBOP activates the group of
SREBP2 regulated genes; however, immunoblot analysis
revealed no increase in the nuclear SREBP2. This might
result from a CAR-dependent up-regulation of Insig1,
which inhibits the SREBP2 cleavage [22]. RT-PCR analysis
of CAR knock-out animals treated with TCPOBOP indi-
cate that up-regulation of cholesterogenic genes and the
SREBP signaling pathway is CAR-dependent. Since no
CAR binding sites were found in the two most responsive
genes, HMG-CoA reductase (Hmgcr) and squalene epoxi-
dase (Sqle), mechanisms other than direct transcriptional
activation by CAR have to be considered. CAR can activate
another common transcription factor, different from
SREPB2, which can bind to proximal promoters of choles-
terogenic genes. Alternatively, a non-activated CAR could
act as a repressor of cholesterogenic genes. Again, in the
absence of true CAR binding sites in promoters of these
genes it is difficult to draw conclusions. However, it was
reported most recently that SF3a3 functions as a co-repres-
Table 6: Expression of genes in knock-out mice treated with TCPOBOP as detected by RT-PCR
Treatment Gene name Genotype
WT CAR -/-
TCPOBOP Hmgcr 2.22 ± 1.38 0.35 ± 0.18*
Sqle 2.18 ± 1.1* 0.69 ± 0.25*
Cyp51a1 1.43 ± 0.89 0.43 ± 0.16*
Insig1 1.86 ± 0.77 0.55 ± 0.24*
Srebp2 1.31 ± 0.73 0.49 ± 0.20*
Cyp3a11 5.82 ± 3.35* 0.44 ± 0.36
Cyp2b10 5750 ± 2805* 3.59 ± 5.61
Untreated CAR -/- vs WT Hmgcr - 4.1 ± 1.26*
Sqle - 2.90 ± 0.55*
Cyp51a1 - 2.81 ± 0.74*
Insig1 - 3.38 ± 1.02*
Srebp2 - 3.95 ± 1.14*
Cyp3a11 - 3.03 ± 1.80
Cyp2b10 - 0.76 ± 0.54
The effect of TCPOBOP and CAR on the expression of cholesterol synthesis and Srebp2 signaling genes as measured by RT-PCR. Cyp3a11 and 
Cyp2b10 serve as positive controls for CAR activated genes. Data represents fold changes ± standard deviation of treated versus vehicle treated or 
untreated CAR -/- versus wild type (WT). All animals were fed standard chow diet. Six animals per group were analyzed and statistical significance 
was determined using Student t-test. Unigene symbols were used as abbreviations. *p < 0.05.BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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sor of CAR transcriptional activity independently of the
presence of TCPOBOP [30].
Conclusion
Activation of CAR by TCPOBOP alters hepatic metabo-
lism in the livers of mice fed normal and cholesterol-con-
taining diets. TCPOBOP increases removal of excess
dietary cholesterol in serum and liver, and lowers serum
glucose and liver gluconeogenesis under conditions of
hyperlipidemia. On the other hand, CAR activation
increases serum triglycerides and liver fatty acid synthesis,
represses adaptation to hyperlipidemia, and lowers
responsiveness of the liver to adiponectin. These latter
effects favor the development of non-alcoholic fatty liver
disease. Finally, CAR affects downstream SREBP2 signal-
ing (without changing nuclear SREBP2 protein levels) and
is thereby involved in the regulation of cholesterol synthe-
sis.
Methods
Mouse experiment and preparation of liver RNA samples
All animal experiments followed the Amsterdam Protocol
on Animal Protection and Welfare and were approved by
the local ethics committee. Four groups (6 animals per
group) of female mice C57BL/6 (Harlan) age between 18
and 19 weeks were housed in normal light-cycle room,
maintained on standard rodent chow (diet 3430, Provimi
Kliba SA, Kaiseraugst, CH), and allowed water and food
ad libitum. One week prior to treatment, two groups of
mice were switched to a 1% (w/w) cholesterol diet (diet
Western 24769, Provimi Kliba SA, Kaiseraugst, CH). One
group of mice from each diet were injected i.p. with either
vehicle (corn oil, Sigma, St Louis, MI, USA) or with 3 mg/
kg TCPOBOP (Bayer Ag, Wuppertal, Germany) in corn
oil. After 24 hours, mice were sacrificed using CO2 suffo-
cation. Blood was transferred into tubes (BD Biosciences-
Pharmingen) and after centrifugation, serum was stored at
-80°C. Left lateral lobes of livers were snap frozen in liq-
uid nitrogen and stored at -80°C. Total RNA was isolated
from liver using TRI-reagent (Sigma, St Louis, MI, USA)
according to the manufacturer's protocol and purified by
ethanol precipitation.
Experiments with CAR-/- mice were performed as
described [22]. Briefly, male C57BL/6J wild type or CAR -
/- mice, age 9–12 weeks, were maintained on standard
laboratory chow and had free access to food and water.
They were maintained in 12-hour light/dark cycle. Six
mice per group were injected i.p. with vehicle (5%DMSO
in corn oil) or with 10 mg/kg TCPOBOP (Bayer Ag, Wup-
pertal, Germany). After 12 hours mice were sacrificed and
total liver RNA was isolated using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA).
Microarray analyses
The Steroltalk cDNA microarrays were prepared as previ-
ously described [31]. Total RNA from each animal was
labeled separately, and a reference sample was prepared
by pooling all RNA samples in the study in equal
amounts. To each RNA sample a spike in RNA was added
and transcribed to Cy3 or Cy5 labeled cDNA using
amino–allyl labeling. Details of the microarray experi-
ment are described in Additional file 3. Classification of
differentially expressed genes was done in BRB-Array
Tools Version 3.7.0 beta_2 release developed by Dr. Rich-
ard Simon and Amy Peng Lam using Class comparison
between groups and significance threshold α = 0.05 and
FDR<0.16. Genes were further annotated using GeneCo-
dis and KEGG pathways [32]. All data have been depos-
ited in GEO database, reference number GSE13688.
Real-time polymerase chain reaction analyses
In studies of diet effect on TCPOBOP activation, analyses
were performed using Platinum®  SYBR®  Green qPCR
SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) on ABI
PRISM 7900 HT (PE Applied Biosystems, Foster City, CA,
USA) according to manufacturer's protocols. In samples
from knock-out livers, analyses were performed using
LightCycler® 480 SYBR Green I Master on LightCycler® 480
(Roche Diagnostics GmbH, Mannheim, Germany), except
Cyp2b10, which was done as described above. 18S rRNA
served as internal control in both studies. Relative tran-
script levels were calculated by the comparative Ct (cycle
threshold) method and -ΔΔCt values were used for statis-
tical analyses [33]. Levene's test for equality of variance
was performed, and Student t-test and a probability of
type I error α = 0.05 was used to determine statistical sig-
nificance in SPSS 14.0 (SPSS Inc., Chicago, Illinois, USA).
Primer sequences and analysis details are provided in
Additional file 3.
Liver sterol analyses
Two frozen liver samples from individual animals were
combined yielding three pools per treatment and sterol
metabolites were isolated and analyzed as described else-
where [34]. Levels of free lathosterol, C4 and total choles-
terol were measured using GC-MS. Lathosterol is an
intermediate of cholesterol biosynthesis and has been
shown to correlate well with the activity of HMG-CoA
reductase [35]. Free lathosterol/total cholesterol ratio was
therefore used as a marker of metabolic rate of liver cho-
lesterol biosynthesis. C4 is an intermediate of classical
bile acid pathway and can be produced only by enzymatic
activity (Björkhem I, personal communications). The
quantity of measured sterols (ng/mg liver) was calculated
using standard curve, and these values were used for sta-
tistical analyses. Details are available in Additional file 3.
Levene's test for equality of variance was performed, and
Student t-test and a probability of type I error α = 0.05BMC Genomics 2009, 10:384 http://www.biomedcentral.com/1471-2164/10/384
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were used to determine statistical significance in SPSS
14.0 (SPSS Inc., Chicago, Illinois, USA). In the case of C4/
cholesterol, ratio variance was not equal and so we
applied Mann-Whitney U test for statistical significance.
Measurements of serum parameters
Total serum cholesterol and triglyceride analyses were per-
formed on RX Daytona analyser by the enzymatic colom-
etric method using Cholesterol CHOD/PAP
(Dimension®) and Triglycerides GPO/PAP kit (Dimen-
sion®) (Randox Laboratories Ltd., Crumlin, UK), respec-
tively. HDL and LDL cholesterol levels were analyzed by
Cobas Mira analyser and direct enzymatic method (Ran-
dox Laboratories Ltd, Crumlin, UK). Glucose was meas-
ured by UV test using hexokinase and glucose 6-
phosphate dehydrogenase (Randox Laboratories Ltd.,
Crumlin, UK) using Cobas Mira analyser. All analyses
were done at Veterinary Faculty, University of Ljubljana.
Immunoblot analyses of nuclear Srebp2
Liver samples from two animals were pooled, yielding 3
biological replicas per treatment and nuclear proteins
were extracted (details see in Additional file 3). Proteins
were analyzed using SDS-PAGE gels NuPAGE® Novex 4–
12% Bis-Tris Gels and run using XCellTM Surelock Mini-
Cell (Invitrogen, Carlsbad, CA, USA) according to manu-
facturer's protocol. Proteins were transferred to PVDF
membrane HybondTM-P (Amersham Biosciences, GE
Healthcare UK limited, Little Chalfont, UK) using XCell
IITM Blot Module and NuPAGE® Transfer Buffer (Invitro-
gen, Carlsbad, CA, USA) according to manufacturer's pro-
tocol. Mouse anti-Srebp2 (BD Biosciences San Jose, CA,
USA) and anti-actin (Sigma, St. Louis, MI, USA) antibod-
ies were used.
Bioinformatical analysis of promoters
Genomic sequences from exon 2 to 10 kb distal promoter
were selected and analyzed by NUBIScan software, search-
ing for DR4, DR3 and ER6 sites with p-value cut-of at 0.05
[21].
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